Compound ID | 2018
Class: Antimicrobial peptide
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor. Inhibits the formation of late-stage peptidoglycan intermediates (lipid intermediates) by inhibiting lipid phosphorylase |
| Description: | Natural product produced by Bacillus licheniformis, composed of a mixture of related compounds. Used for minor skin wounds and eye infections often in combination with other antibiotics. |
| Year first mentioned: | 1943 |
| Highest development stage: | Approved by FDA in 1948 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/439542 |
| Guide to Pharmacology: | bacitracin A |
| Citation: | https://www.nature.com/articles/s41598-017-01267-5 |